XML 60 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Operating Activities    
Net income $ 53,484 $ 33,899
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 6,562 6,591
Deferred income taxes 4,355 12,391
Amortization of deferred financing costs 1,975 2,060
Stock-based compensation costs 2,487 1,973
Amortization of debt discount 798 812
Lease termination costs 0 975
(Gain) loss on sale or disposal of equipment (3) 51
Changes in operating assets and liabilities, net of effects from acquisitions    
Accounts receivable (5,712) (24,530)
Inventories 821 (2,904)
Prepaid expenses and other current assets 2,619 5,556
Accounts payable (1,125) 15,150
Accrued liabilities (10,663) 8,350
Net cash provided by operating activities 55,598 60,374
Investing Activities    
Purchases of property and equipment (2,319) (5,266)
Proceeds from the sale of property and equipment 3 15
Acquisition of brands from GSK purchase price adjustments 0 (226)
Acquisition of Care Pharmaceuticals, less cash acquired (55,215) 0
Net cash used in investing activities (57,531) (5,477)
Financing Activities    
Repayments of long-term debt (7,500) (70,000)
Repayments under revolving credit agreement (35,500) (8,000)
Borrowings under revolving credit agreement 50,000 33,000
Payment of deferred financing costs (275) 0
Proceeds from exercise of stock options 5,143 80
Excess tax benefits from share-based awards 1,350 0
Fair value of shares surrendered as payment of tax withholding (278) 0
Net cash provided by (used in) financing activities 12,940 (44,920)
Effects of exchange rate changes on cash and cash equivalents 156 14
Increase in cash and cash equivalents 11,163 9,991
Cash and cash equivalents - beginning of period 15,670 19,015
Cash and cash equivalents - end of period 26,833 29,006
Interest paid 29,516 36,524
Income taxes paid $ 8,468 $ 656